IMMULITE 2000 PROSTATE SPECIFIC ANTIGEN
Report
- Report Number
- 2432235-2013-00267
- Event Type
- Malfunction
- Date Received
- July 2, 2013
- Date of Event
- October 10, 2013
- Report Date
- June 13, 2013
- Manufacturer
- SIEMENS HEALTHCARE DIAGNOSTICS
- Product Code
- MTF
- PMA / PMN Number
- P930027
- Removal / Correction Number
- 2432235-06/25/13-003-R
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
SIEMENS HAS INVESTIGATED THE INCIDENCE OF POSITIVE BIAS ON IMMULITE 2000 PSA ASSAY, AND A POSITIVE BIAS OF 20-23 PERCENT RELATIVE TO WHO 96/670 HAS BEEN CONFIRMED. AN URGENT FIELD SAFETY NOTICE (UFSN) - UFSN 4006 IMMULITE/IMMULITE 2000/IMMULITE 2000 XPI PSA POSITIVE BIAS TO WHO 96/670 - WAS SENT TO CUSTOMERS IN JUNE 2013. THE UFSN STATES THAT CUSTOMERS ARE TO DISCONTINUE USE OF THE PRODUCT AND DISCARD AFFECTED KITS REMAINING IN THEIR INVENTORY.
THE INITIAL MDR 2432235-2013-00267 WAS FILED ON JULY 2, 2013. IN THE ORIGINAL MDR 2432235-2013-00267 FILED ON JULY 2, 2013 THE DATE OF EVENT WAS INCORRECTLY STATED. THE CORRECTED DATE IS (B)(6) 2012.ADDITIONAL INFORMATION (07/03/2013): THE CAUSE OF THE POSITIVE BIAS ON THE IMMULITE 2000 PSA ASSAY IS A CONTROL SYSTEM DEFICIENCY.
THE CUSTOMER HAS OBSERVED HIGH BIAS FOR THE IMMULITE PROSTATE SPECIFIC ANTIGEN (PSA) WHEN USING REAGENT LOT NUMBERS 379 AND 380. THE ASSAY WAS RUN ON AN IMMULITE 2000 INSTRUMENT, AND THE HIGH BIAS AFFECTED BIORAD QUALITY CONTROL, AND SIEMENS QUALITY CONTROL RESULTS. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE HIGH BIAS ON THE PSA ASSAY WHEN USING KIT LOTS 378 AND 379.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 301188 | IMMULITE 2000 PROSTATE SPECIFIC ANTIGEN | IMMULITE 2000 PROSTATE SPECIFIC ANTIGEN | MTF | SIEMENS HEALTHCARE DIAGNOSTICS | IMMULITE 2000 PROSTATE SPECIFIC ANTIGEN | 379, 380 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |